Q2 2026 PTC Therapeutics Inc Earnings Call Transcript
Key Points
- Record Q2 2026 total revenue of $361 million, with product revenue of $239 million, leading to raised full-year 2026 product revenue guidance to $850-$950 million and total revenue to $1.18-$1.28 billion.
- Strong global launch momentum for Sephience, with Q2 revenue of $151 million (up 21% quarter-over-quarter) and 1,647 commercial patients on therapy globally, including 100% penetration of US Centers of Excellence.
- Positive 24-month interim data from PIVOT-HD study for vatiquinone in Huntington's disease, showing dose-dependent slowing of disease progression (52% average slowing in stage 2 cohort) with a favorable safety profile.
- Robust cash position of $2.23 billion as of June 30, 2026, with strategic refinancing of convertible notes at 0% coupon and 40% conversion premium, positioning the company for potential cash flow breakeven in 2026.
- Pipeline advancements, including initiation of Phase 1 study for PTC612 (NLRP3 inhibitor) and selection of development candidate PTC-303 for MSH3 splicing program, expected to enter clinic in 2027.
- International expansion for Sephience is accelerating, with Japan launch exceeding expectations, pricing on par with US locked for 10 years, and early access programs in Europe, Latin America, and Middle East contributing to revenue.
- Duchenne muscular dystrophy (DMD) franchise faces significant headwinds, including generic competition for Emflaza and challenges in larger markets with group purchase orders, though revenue was $67 million in Q2.
- Vatiquinone's approval path remains uncertain, with Phase 3 study as base case and FDA discussions for potential accelerated approval still pending, adding regulatory risk.
- Friedreich's ataxia program (vatiquinone) requires a new open-label trial (PROVE-FA) with natural history comparator for NDA resubmission, delaying potential approval and adding development costs.
- Pricing and reimbursement negotiations in Germany for Sephience are taking longer than expected, with finalization now anticipated in Q3 or Q4 2026, potentially impacting European revenue timing.
- Discontinuation rate for Sephience is approximately 20%, which, while low, indicates some patient attrition that could affect long-term revenue growth.
- The company's reliance on early access programs for international revenue may lead to variability in revenue recognition and pricing across different markets, complicating financial forecasting.
Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics second-quarter 2026 earnings conference call. (Operator Instructions) Today's conference is being recorded.
I would like to turn the conference over to Ellen Cavaleri, Head of Investor Relations. Please go ahead.
Good afternoon, and thank you for joining us to discuss PTC Therapeutics' second-quarter 2026 corporate update and financial results. I'm joined today by our Chief Executive Officer, Dr. Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Pierre Gravier.
Today's call will include forward-looking statements based on our current expectations. These statements are subject to certain risks and uncertainties, and actual results may differ materially. Please review the slide posted on our Investor Relations website in conjunction with the call, which contains information about our forward-looking statements and our most recent quarterly report on Form 10-Q and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
